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

Worldwide, breast cancer is one of the most common cancers and a leading 
death cause amongst women (Ferlay et al., 2007; Jemal et al., 2009). Many factors 
contribute to the development and progression of breast cancer. Interestingly, sex 
hormones such as estrogen and progesterone are well known factors critically involved 
in mammary tumorigenesis and recently it has been shown that women undergoing 
combined hormonal replacement therapy (HRT) have an increased risk of developing 
breast cancer. In particular, synthetic progesterone derivatives like 
medroxyprogesterone acetate (MPA) which are widely used by millions of women in 
the form of HRT and contraceptives appear to markedly increase the risk of developing 
breast cancer (Beral, 2003; Rossouw et al., 2002). However, the mechanism how MPA 
is linked to breast cancer on a molecular level is still poorly understood.  
Receptor activator of NFκB (RANK) and its ligand RANKL are essential and 
central regulators of osteoclast differentiation and osteoclast function (Kong et al., 
1999b). The discovery of these molecules has unquestionably significantly contributed 
to the understanding of the molecular mechanisms of normal bone metabolism and bone 
disease. Moreover RANK and RANKL are also crucial in pregnancy-dependent 
mammary gland formation (Fata et al., 2000). Embedded in a hormonal regulatory 
network the RANK/RANKL pathway initiates proliferation and differentiation of 
terminal end buds to lobuloalveolar structures via activation of the Id2 pathway (Kim et 
al., 2006) and the NFκB – CyclinD1 axis (Cao et al., 2001). Intriguingly, we here report 
that in vivo MPA administration results in massive upregulation of RANKL expression 
in female mice. Most importantly, we show that tissue specific inactivation of RANK in 
mammary epithelial cells results in a significantly delayed onset of breast cancer in 
response to MPA/DMBA treatment. On a molecular level it appears that loss of RANK 
leads to impaired NFκB and Id2 activation resulting in a block in proliferation. 
Moreover we observed that MPA-induced RANKL expression protects of γ-irradiation-
induced cell death, thus providing a prerequisite for the development of cancer. These 
data provide the first demonstration that RANK/RANKL control the development of 
hormone-driven breast cancer.  


 Weltweit ist Brustkrebs eine der häufigsten Krebsarten und zählt unter Frauen zu 
einer der führenden Todesursachen (Ferlay et al., 2007; Jemal et al., 2009). Viele 
Faktoren sind bekannt, die zur Entstehung und zur Progression von Brustkrebs 
beitragen. Auch Geschlechtshormone, wie Östrogene und Progesteron spielen eine 
kritische Rolle in manchen Brustkrebsarten. Kürzlichen Berichten zufolge ist die 
Wahrscheinlichkeit für Frauen, die sich einer Hormonersatztherapie unterziehen, 
grösser an Brustkrebs zu erkranken. Im speziellen werden syntethische Progesterone-
Derivate (Progestine) wie Medroxyprogesteron Acetat (MPA) welches Millionen 
Frauen in Form von Hormonersatztherapeutika und hormonelle Kontrazeptiva zu sich 
nehmen, mit diesem erhöhten Brustkrebsrisiko in Verbindung gebracht. Trotzdem sind 
die genauen molekularen Mechanismen, welche Rolle Progestine in Brustkrebs spielen, 
noch wenig verstanden. 
Rezeptor Aktivator von NFκB (RANK) und sein Ligand RANKL sind essentielle 
Regulatoren für die Differenzierung und Funktion von Osteoklasten. Unfraglich hat die 
Entdeckung dieser Moleküle erheblich dazu beigetragen die molekularen Mechanismen 
im Knochenstoffwechsel und von Knochenerkrankungen besser zu verstehen. 
Außerdem sind RANK und RANKL auch wesentliche Faktoren für die der Entwicklung 
der Brustdrüsen während der Schwangerschaft. Über hormonelle Regulation und die 
Aktivierung von Id2 (Kim et al., 2006), NFκB und CyclinD1 (Cao et al., 2001) 
induzieren RANK und RANKL die Proliferation und Differenzierung von terminalen 
Endknospen zu lobuloalveolaren Strukturen. Interessanterweise berichten wir hier, dass 
die in vivo Verabreichung von Medroxyprogesteron Acetat zu einer Hochregulierung 
der RANKL-Expression in weiblichen Mäusen führt. Außerdem zeigen wir, dass die 
gewebsspezifische Inaktivierung von RANK in Brustepithelzellen nach 
Progesteron/DMBA Adminsitration zu einer signifikant späteren Entstehung von 
Brusttumoren führt. Auf molekularer Ebene scheint es, als ob die Inaktivierung von 
RANK in einer Beeinträchtigung von Id2 und NFκB und somit in einem 
Proliferationsblock resultiert. Weiters konnten wir beobachten dass die MPA-induzierte 
Expression von RANKL Brustepithelialzellen vor dem programmierten Zelltod 
induziert durch γ-Bestrahlung schützt. Dies stellt eine Prärequisite für die Entstehung 
von Krebs dar. Zusammenfassend zeigen wir hier zum ersten Mal, dass RANK und 


RANKL, bekannt als Schlüsselmoleküle im Knochenmetabolismus auch die Entstehung 
von hormonabhänigigen primärem Brustkrebs kontrollieren.  


1. Introduction 
 
1.1. RANK, RANKL and OPG – an overview 
´ Over the course of our whole lifetimes bone is continuously being remodelled 
through the balanced activity of bone depositing osteoblasts and bone resorbing 
osteoclasts (Boyle et al., 2003; Karsenty and Wagner, 2002; Theill et al., 2002). Any 
perturbations which cause an imbalance between these dynamic processes of osteoblast 
and osteoclast activity can lead to severe skeletal diseases such as osteoporosis and 
osteopetrosis (Boyle et al., 2003; Karsenty and Wagner, 2002; Theill et al., 2002). 
Osteopetrosis, a state of abnormally increased bone density mainly results from very 
rare heritable conditions. By contrast, bone loss or osteoporosis is much more prevalent 
and hundreds of millions of people worldwide are affected by this devastating disease 
(Wada et al., 2006). Most frequently osteoporosis is observed in postmenopausal 
women, rheumatoid arthritis, immobilized patients, early childhood leukaemia, 
periodontitis and even astronauts as a consequence of zero gravity (Boyle et al., 2003; 
Theill et al., 2002; Wronski and Morey, 1983).  
A new era in bone research has just started a decade ago with the discovery of 
three essential and central molecules of bone turnover. These key molecules are the 
receptor activator of NFκB (RANK), its ligand RANKL and the RANKL-decoy 
receptor osteoprotegerin (OPG). Binding of RANKL to its receptor RANK initiates the 
development and activation of osteoclasts whereas OPG effectively inhibits 
osteoclastogenesis by functioning as a molecular decoy receptor for RANKL (Simonet 
et al., 1997; Yasuda et al., 1998b). Unquestionable, the discovery of RANK, RANKL 
and OPG has significantly contributed to our understanding of the molecular processes 
underlying bone diseases. Most importantly, RANK, RANKL and OPG have become 
principal targets in the development of new therapies which might be used one day to 
treat hundreds of millions of people suffering diseases associated with bone loss 
(Leibbrandt and Penninger, 2008).  
 
 

In the late 1990ies the Tumor necrosis factor (TNF) family member cytokine 
RANKL, also known as TRANCE (TNF-related activation-induced cytokine), ODF 
(osteoclast differentiation factor) and OPGL (OPG ligand) was discovered almost 
simultaneously by four independent groups (Anderson et al., 1997; Lacey et al., 1998; 
Wong et al., 1997b; Yasuda et al., 1998b). Whereas Anderson et al. and Wong et al. 
associated RANKL with essential functions in the immune system (Anderson et al., 
1997; Wong et al., 1997b), Lacey et al. and Yasuda et al. identified RANKL as a ligand 
for OPG, inducing osteoclastogenesis (Lacey et al., 1998; Yasuda et al., 1998b). The 
RANKL gene encodes a type II transmembrane protein consisting of a membrane-
anchoring domain, a connecting stalk and a receptor-binding ectodomain. Human und 
murine RANKL are highly conserved and are synthesized as approximately 316 amino 
acid, either membrane bound or soluble, glycoproteins. The soluble form is either 
derived from proteolytic cleavage or alternative splicing (Wada et al., 2006). All 
described RANKL isoforms can mediate osteoclastgenesis in vitro (Ikeda et al., 2003; 
Suzuki et al., 2004). Interestingly, it has been reported that co-expression of different 
isoforms seems to provoke inhibitory effects. Thus, the control of osteoclastogenesis 
might also require regulated expression of RANKL isoforms (Ikeda et al., 2003; Suzuki 
et al., 2004). RANKL is highly expressed in skeletal and primary and secondary 
lymphoid tissues; but RANKL expression can also be detected in keratinocytes of the 
skin, epithelial cells of the mammary gland, heart, skeletal muscle, lung, stomach, 
placenta, thyroid gland and brain (Leibbrandt and Penninger, 2008).  
1997, RANK, the signaling receptor for RANKL was identified by several 
groups as a receptor involved in osteoclastogenesis, enhanced T-cell growth and 
survival of dendritic cells (Anderson et al., 1997; Hsu et al., 1999; Nakagawa et al., 
1998). RANK encodes a type I transmembrane glycoprotein consisting of a short signal 
peptide, an extracellular domain, a transmembrane domain and a large cytoplasmic 
domain. Like many Tumornecrosis factor receptor (TNFR) members, RANK assembles 
into a trimeric complex on the cell surface prior to ligand binding (Chan et al., 2000; 
Locksley et al., 2001). RANK message is detected in skeletal muscle, thymus, liver, 
colon, small intestine, adrenal gland, osteoclasts, mammary epithelial cells prostate and 
pancreas (Leibbrandt and Penninger, 2009). 
The third molecule of the triade, Osteoprotegerin (OPG), inhibits 
RANK/RANKL signaling effectively by competing with RANK for RANKL binding 

(Simonet et al., 1997; Yasuda et al., 1998a). Therefore, OPG is also referred to as 
protector of the bone, as it prevents RANK/RANKL mediated bone degradation. OPG 
is a member of the TNFR-family and is synthesized as a 55-kDa glycoprotein. Unlike 
other TNFR-family members, OPG does not assemble into a trimeric molecule but is 
secreted as a 110-kDa homodimer. OPG is most abundantly expressed in the brain, 
liver, lung, heart, kidney, skeletal muscle, skin, intestines, calvaria, stomach testis and 
placenta (Tan et al., 1997). 
 
1.2. The classical role of the RANKL-RANK-OPG axis in bone metabolism 
Genetic manipulation of RANKL, RANK and OPG in mice contributed greatly 
to our understanding of its functions in the skeleton. Unambiguously, the first 
breakthrough was to show that the RANK-RANKL-OPG axis is essential for normal 
and pathologic bone metabolism. OPG was the first molecule of the triade to be shown 
to be critically required for the maintenance of postnatal bone mass in vivo. Mice 
overexpressing OPG and mice treated with recombinant OPG suffer from severe 
osteopetrosis (Simonet et al., 1997), whereas mice lacking OPG in the germline develop 
early-onset osteoporosis (Bucay et al., 1998). However, at this time it was only 
speculation that OPG might inhibit an activator of osteoclastogenesis. But only a few 
months later, targeted deletion of RANKL and RANK in mice provided the link 
between these three molecules and bone metabolism. Both, RANKL (Kong et al., 
1999b) and RANK knockout mice (Dougall et al., 1999; Li et al., 2000) exhibit severe 
osteopetrosis and impaired tooth eruption due to a complete lack of osteoclasts. Thus, it 
was shown that whereas RANK and RANKL are positively regulating 
osteoclastogenesis, OPG is essential for counterbalancing this pathway by functioning 
as a natural decoy receptor. RANK, RANKL and OPG are therefore the key molecules 
driving osteclast induced bone turnover (Figure 1).  
RANK/RANKL-functions underly various regulatory mechanisms. In particular, 
many cytokines influence the RANK/RANKL-system in bone metabolism. Macrophage 
colony-stiumlating factor (M-CSF) is a cytokine essential for RANKL-induced 
osteoclastogenesis (Arai et al., 1999). M-CSF is the most important survival factor for 
osteoclast-progenitor cells and enables the commitment of precursor cells into the 
osteoclast lineage (Arai et al., 1999).  

Moreover, RANKL-dependent osteoclastogenesis has also been shown to be 
induced by the Transforming growth factor (TGF) family members TGFβ1 and activin 
A in vitro (Koseki et al., 2002). Furthermore, also Tumor necrosis factor alpha (TNFα), 
a cytokine which is abundant at sites of inflammation considerably influences RANKL-
mediated bone turn over (Zhang et al., 2001). Therefore, osteoclastogenesis is enhanced 
under pro-inflammatory conditions due to RANKL and TNFα cooperation. Evidently, 
chronic inflammation is often associated with bone loss. Thus, the production of 
cytokines is one of the reasons for enhanced bone resorption during inflammatory 
events (Theill et al., 2002). 
Another very powerful regulatory mechanism of the RANK/RANKL system are 
hormones. In particular, RANK activation is under a strong influence of estrogens and 
androgens. Both sex hormones suppress RANKL-induced osteoclast differentiation by 
interfering with the JNK-c-Jun pathway (Syed and Khosla, 2005). Moreover, estrogens 
and androgens also induce the expression of the decoy recptor OPG, thus directly 
controlling RANKL-mediated bone turnover (Syed and Khosla, 2005). Therefore, the 
loss of estrogen production in the ovaries of postmenopausal women often results in 
progressive bone loss and osteoporosis. Previously, it has been shown that estrogen 
specifically induces apoptosis in trabecular bones via upregulation of Fas ligand 
expression in mice (Nakamura et al., 2007). Thus, one plausible explanation for the 
osteoprotective function of estrogen is that it regulates the life span of mature 
osteoclasts via induction of the death-inducing Fas/FasL pair (Nakamura et al., 2007). 
 
The functional role of the RANK-RANKL-OPG axis in osteoclastogenesis and 
bone remodelling is conserved in humans (Wada et al., 2006). Therefore, 
RANK/RANKL is relevant to many human bone diseases. For example, autosomal-
recessive osteopetrosis (ARO) is a rare heritable bone disease which is usually 
associated with defects in bone resorption either due to a defect in osteoclastogenesis or 
due to non-functional mature osteoclasts (Sobacchi et al., 2007). Recently it has been 
shown that impaired RANK/RANKL signaling is associated with a new osteoclast-poor 
subset of ARO. All 6 individuals suffering from this ARO-subtype harbour mutations in 
RANKL (Sobacchi et al., 2007). Moreover, two siblings from a Turkish consanguineous 
family and 6 more patients from unrelated families suffering ARO were identified to 

harbour a homozygous mutation in the RANK gene, thus clearly emphasizing the 
clinical importance of RANK mutations in ARO patients (Guerrini et al., 2008). 
Another bone disease resulting from an autosomal recessive osteopathy is known as 
Juvenile Paget disease. Patients suffering from this disease are characterized by rapid 
remodelling of woven bone, osteopenia, fractures and progressive deformation of the 
skeleton (Ralston, 2008). Intriguingly, these patients have several mutations affecting 
the ligand binding domain of OPG, thereby linking the RANK/RANKL system to this 
disease (Hughes et al., 2000).  
However, compared to ARO and Juvenile Paget diseases, both of which are 
characterized by increased bone mass, pathologically decreased bone mass is far more 
prevalent. Diseases like postmenopausal osteoporosis, periodontitis, rheumatoid 
arthritis, childhood leukaemia or chronic infections are associated with extensive bone 
loss resulting from deregulated RANK/RANKL signaling (Leibbrandt and Penninger, 
2008). 
Moreover, RANK and RANKL have been shown to play a critical role in 
metastasis to bone (Jones et al., 2006). Metastases are a frequent complication of many 
cancers causing severe pain and increased disease burden. The microenvironment of the 
host tissue plays a considerable role in the metastatic behaviour and preferred migration 
sites of cancer cells (Joyce and Pollard, 2009). Intriguingly, it was shown that RANKL 
triggers the migration of human epithelial cancer cells and melanoma cells expressing 
the receptor RANK. Moreover, the inhibition of RANKL by osteoprotegerin 
significantly reduces the tumor burden in bone but not in other organs in vivo. Thus, 
RANKL production in bone tissue provides a very fertile milieu for metastases (Jones et 
al., 2006). Since RANK was also found to be expressed on breast cancer cells of 
patients, RANKL has also an important role in cell migration and tissue specific-
metastatic behaviour in humans (Jones et al., 2006). 
Importantly, extensive research during the last years has enabled the 
development of denosumab (AMG 162), a monoclonal IgG2 antibody to human 
RANKL which has just passed phase three of clinical trials (Cummings et al., 2009; 
Smith et al., 2009, Bone et al., 2008; Cohen et al., 2008; Lipton et al., 2007). Thus, in 
the near future a promising treatment for postmenopausal osteoporosis, cancer-induced 
bone diseases, metastasis to bone and rheumatoid arthritis might be available.  

 
 
 
 
 
 
 
 
 
 
Figure 1. Regulation of osteoclast formation in bones. RANKL expression in 
osteoclasts can be induced by calciotropic factors such as Vitamin D3, 
Prostaglandin E2 (PGE2), Parathyroid hormone (PTH), Parathyroid related-
hormone peptide (PTHrP), Tumor necrosis factor alpha (TNFα), Interleukines 1, 
11 and 17 (IL-1, 11 ,17) and the synthetic glucocorticoid Dexamethasone. Binding 
of RANKL to its receptor RANK on the surface of haematopoietic progenitor cells 
induces osteoclast differentiation in the presence of the survival factor M-CSF 
(Macrophage-colony stimulating factor). In mature osteoclasts binding of RANKL 
to RANK stimulates bone resorbing activity and promotes survival of the 
osteoclasts. The decoy receptor OPG is produced by osteoblasts and effectively 
inhibits osteoclastogenesis and osteoclast activation by binding to RANKL in the 
bone environment. Moreover, estrogen can accelerate OPG production on 
osteoblasts, which might, in part, explain postmenopausal osteoporosis. 
 

1.3. RANK(L) activated signaling pathways 
Given the broad expression pattern and the pleiotropic in vivo functions of 
RANK and RANKL it is evidently of great interest to study RANK/RANKL signaling 
pathways. Most importantly, knowledge about RANK/RANKL downstream targets is 
crucial to identify new therapeutic targets for severe diseases involving impaired 
RANK/RANKL functions (Figure 2).  
Like all TNF-family members RANK does not posses any kinase activity but 
initates downstream signaling via recruiting various adaptor molecules (Wajant et al., 
2003). The binding of Tumor necrosis factor related adaptor proteins (TRAFs) is 
common to all members of the TNF-family (Inoue et al., 2000). In its cytoplasmic tail 
RANK contains binding sites for TRAF2, 5 and 6. Functionally, it has been shown that 
TRAF6 is the major downstream transducer of RANK activation (Darnay et al., 1998; 
Darnay et al., 1999; Wong et al., 1998). Thereto, TRAF6 knockout mice exhibit severe 
osteopetrosis due to a partial block in osteoclast development and impaired osteoclast 
activation (Lomaga et al., 1999). By contrast, TRAF2 and TRAF5 appear to play a 
minor role in RANK/RANKL-mediated osteoclastogenesis (Kanazawa et al., 2003; 
Kanazawa and Kudo, 2005). 
GRB2 associated binder 2 (GAB2) is another adaptor molecule that functions 
downstream of RANK activation. In particular, GAB2 is important for RANK-induced 
NFκB, Akt/PKB and JNK signaling (Wada et al., 2005). GAB2 knockout mice exhibit 
severe osteopetrosis due to defective osteoclast differentiation. Moreover, it was shown 
that inactivation of GAB2 is also critical in the differentiation of human progenitor cells 
into osteoclastogenesis. Thus, GAB2 is a key molecuclar scaffold protein that controls 
osteoclastogenesis and bone homeostasis in mice and human (Wada et al., 2005). 
Nuclear factor kappa B (NFκB) is a major regulator of cell fates and strongly 
activated upon RANK stimulation (Karin and Lin, 2002). In particular, TRAF6 
association is essential for RANKL-induced NFκB signaling (Darnay et al., 1999; 
Wong et al., 1998). Mammals express five Rel (NFκB) proteins referred to as RelA 
(p65), c-Rel, RelB, NFκB1 (p105) and NFκB2 (p100). Whereas RelA, c-Rel and RelB 
are synthesized as mature products, p105 and p100 are proteolytically processed into 
mature p50 and p52 NFκB proteins (Karin and Lin, 2002). Two Rel proteins, namely 
NFκB1 and NFκB2 have been shown to be required for osteoclastogenesis in vivo and 

mice lacking both p50 and p52 exhibit severe osteopetrosis (Iotsova et al., 1997). 
Furthermore, IκB kinases (IKKα, IKKβ and IKKγ) have also been implicated in 
RANK/RANKL signaling. Whereas IKKβ is required for RANK/RANKL-induced 
osteoclastogenesis in vitro and in vivo, the role of IKKα seems to be marginal in vivo 
(Ruocco et al., 2005). Importantly in human patients, IKKγ mutations are associated 
with osteopetrotic patients suffering X-linked osteopetrosis, lymphedema, anhidrotic 
ectodermal dysplasia and immunodeficdiency (Doffinger et al., 2001). Therefore the 
NFκB pathway is also relevant for activation and function of osteoclasts in humans.  
Stimulation of RANK also results in the activation of members of the mitogen 
activated protein kinase family (MAPK family). MAPK signaling is an evolutionarily 
conserved mechanism of cells to respond to environmental stresses, thereby controlling 
cell survival and adaptation. The family of MAPKs consist of p38-MAPKs, c-Jun N-
terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs) (Chang and 
Karin, 2001). Pharmogological inhibiton of the p38-MAPK isoforms p38α and p38β 
blocks RANKL-induced osteoclast differentiation (Matsumoto et al., 2000). Thus the 
p38-MAPKs appear to be mediators of RANKL-induced osteoclast development from 
haematopoietic precursor cells. Moreover, it has also been shown that JNKs and their 
direct upstream kinase MKK7 are required for osteoclastogenesis in vitro (David et al., 
2002; Yamamoto et al., 2002). In addition, JNKs control members of the AP-1 family 
of transcription factors such as c-Jun, JunB, C-Fos and Fra all of which have been 
shown to play roles in bone metabolism (David et al., 2002; Kenner et al., 2004; 
Wagner, 2002). Furthermore, RANK activation results in the induction of ERK which 
also increases osteoclastogenesis (Hotokezaka et al., 2002). However, since the NFκB 
and the MAPK pathways are common to many other signaling processes in different 
organs the suitability of these molecules as therapeutic targets is rather questionable.  
 One key transcription factor in RANKL-induced osteclastogenesis is the nuclear 
factor of activated T cells, calcineurin dependent 1 (NFATc1) (Takayanagi et al., 
2002a). NFATc1 was identified in a genome-wide screen for genes that are specifically 
linked to osteoclast differentiation. In the presence of RANKL the expression of 
NFATc1 is significantly upregulated leading to terminal differentiation of osteoclasts 
(Takayanagi et al., 2002a). Targeted deletion of NFATc1 in mice leads to a significant 
defect in osteoclastogenesis thus resulting in osteopetrosis (Aliprantis et al., 2008). 
Importantly, RANKL-mediated activation of NFATc1 requires the calcium-dependent 

phosphatase calcineurin (Takayanagi et al., 2002a). The RANK/RANKL pathway is 
coupled to calcium signaling by the phosphatidylinsoitol-related enzyme phospholipase 
C (PLC). The activation of PLCγ via Tec-kinase family members results in the 
mobilization of calcium from intracellular stores, thus allowing the activation of the 
essential transcription factor NFATc1 via calcineurin ( Mao et al., 2006, Komarova et 
al., 2003; Takayanagi, 2005; Takayanagi et al., 2002a, ). 
 Furthermore, RANKL-induced osteoclastogenesis also requires the activation of 
the anti-apoptotic serine/threonine proteinkinase B (Akt/PKB) via the proto-oncogene c-
src and the inositol lipid metabolism (Leibbrandt and Penninger, 2008). Targeted 
disruption of c-src or the phosphoinositide phosphatase SHIP1 in mice leads to 
osteopetrosis, thus emphasising the critical role of this pathway in bone metabolism. 
Most importantly, c-src might be a suitable target for future treatment of osteoporosis 
and bone loss in arthritis.  
 Besides the major RANK/RANKL-activated signaling pathways fine 
tuning of RANKL-induced osteoclastogenesis and bone turnover requires the 
interaction with many cytokines. The T cell derived cytokine, Interferon gamma 
(INFγ) reduces RANK signaling by accelerating the degradation of the essential adaptor 
protein TRAF6. Moreover, it has been reported that RANKL-induced Interferon beta 
(INFβ) expression in osteoclast precursor cells also inhibits RANK-activity via 
interfering with c-Fos (Takayanagi et al., 2002b). Importantly, the interactions between 
bone and cytokines can also result in a variety of pathologic effects (Lee et al., 2008). 
Thus, the understanding of the roles of cytokines in bone metabolism can lead to the 
development of better therapeutic strategies. 
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Figure 2. RANK/RANKL downstream signaling pathways. Schematic 
illustration of known signaling cascades downstream of RANK/RANKL. RANKL 
binds and activates its receptor RANK, thus leading osteoclast differentiation and 
activation and survival of mature osteoclasts which ultimately results in bone 
resorption. OPG inhibits RANK activation by efficiently competing for RANKL 
binding. RANKL-stimulation induces the activation of Akt/PKB, MAPKs and 
NFκB through recruitment of adaptor molecules such as TRAFs, GAB2 and c-
SRC. RANK/RANKL-mediated phosphatidylinositol signaling results in the 
activation of PKB and SHIP1 and the anti-apoptotic kinase Akt/PKC. Activation 
of MAPK family members induces the expression of AP1 family members such as 
Jun, Fos and Fra that are involved in osteoclastogenesis. 
 

1.4. Beyond bones 
Surprisingly, detailed analysis of RANK-/- and RANKL-/- mice revealed another 
entirely unexpected phenotype. In addition to the severe bone disorder, both mutant 
mouse strains lack all lymph nodes but display normal development of Peyer’s patches 
(Kong et al., 1999b). Since it had been assumed that lymph node organogenesis and the 
development of Peyer’s patches is genetically coupled (Futterer et al., 1998) these 
findings provided the first evidence that these two developmental events underlie 
different genetical regulations. The biogenesis of primordial lymph nodes depends on 
the concerted activity of several cell lineages such as fibroblasts, macrophages, reticular 
cells and endothelial cells. Thereafter, these primordial lymphnodes populated with T 
and B cells and CD4+CD3-LTβ+ cells that differentiate into natural killer (NK) cells, 
antigen presenting cells (APCs) and follicular cells in order to generate mature compact 
nodes. So far, several studies have suggested that impaired lymph node development in 
RANK-/- and RANKL-/- mutant mice is neither due to restricted expression of RANK 
and RANKL in secondary lymphoid organs (Boyle et al., 2003; Simonet et al., 1997) 
nor due to cellular homing defects of RANKL deficient lymphocytes (Kong et al., 
1999b). However, there is some indication that RANKL is involved in the development 
of lymph node morphogenesis by regulating the colonization and cluster formation of 
α4β7+CD45+CD4+CD3- in lymph nodes (Kim et al., 2000). But still, the exact molecular 
mechanisms how RANK and RANKL regulate lymph node formation as well as the 
link between lymph node and Peyer’s patch development remain undefined.  
Furthermore, RANK and RANKL are also important regulators of interactions 
between dendritic cells (DCs) and T cells. Dendritic cells are hematopoietic cells, 
specialized to initiate T cell immunity. Immature DCs reside in peripheral tissues 
waiting to capture and process antigen. In response to antigen contact and inflammatory 
stimuli they undergo maturation and migrate to T cell sites in secondary lymphoid 
organs where they present antigen to naïve T cells. After the event of antigen-
presentation DCs are rapidly eliminated in order to avoid excessive immune responses 
(Banchereau and Steinman, 1998; Ingulli et al., 1997; Leibbrandt and Penninger, 2008). 
For example, it has been shown that prolonged DC survival is critical in patients with 
autoimmune lymphoproliferative syndrome (ALPS) (Wang et al., 1999). RANK and 
RANKL interactions between DCs and active T cells appear to positively regulate DC 
survival by upregulating the expression of the essential T cell co-stimulation factor 

CD40 and of the anti-apoptotic factor Bcl-XL (Anderson et al., 1997; Josien et al., 
2000; Wong et al., 1997a). Moreover it has been observed that OPG can bind to the 
TNF-family molecule TRAIL which is produced by activated T cells in order to induce 
death of DCs in vitro (Emery et al., 1998; Yun et al., 1998). Whether OPG-TRAIL 
interactions are also relevant in vivo still needs to be elucidated. Since modification DC 
survival could be useful in anti-tumor therapy and treatment of autoimmune diseases 
further research in this direction is ongoing.  
In addition, epidermal RANKL which is strongly upregulated upon UV-
irradiation in the skin has been shown to control peripheral homeostasis of CD4+CD25+ 
regulatory T-cells via activating dendritic cells (Loser et al., 2006). Regulatory 
CD4+CD25+ T cells (Tregs) are important for the avoidance of autoimmunity by 
suppressing autoreactive T cells (Sakaguchi, 2005). Thus, by controlling regulatory T 
cell numbers cutaneous RANK and RANKL appear to play a crucial role in the 
suppression of autoimmunity (Loser et al., 2006). Therefore, new therapeutic 
approaches for allergies and systemic autoimmunity might be based on the 
RANK/RANKL system.  
Importantly, RANK and RANKL control also the development of AIRE+ thymic 
epithelial cells in the thymus (Rossi et al., 2007). AIRE+ cells are a subtype of thymic 
meduallary epithelial cells (mTECs) important for the maintenance of self-tolferance 
(Anderson et al., 2002). RANKL which is expressed on a CD4+3- lymphoid tissue 
inducer cell population is required to mediate the development of CD80-Aire- mTECs to 
CD80+Aire+ mTECs (Rossi et al., 2007) (Akiyama et al., 2008; Hikosaka et al., 2008). 
Thus, the RANK/RANKL system is also involved in regulating central tolerance.  
The link between RANK/RANKL in bones and in the immune system lead to 
the emerge of a new research field referred to as osteoimmunology (Rho et al., 2004). 
Since activated T cells express RANKL the question arouse whether T-cell derived 
RANKL can also regulate osteoclast development and activity. Indeed it turned out the 
T cells are able to mediate bone turnover in vitro and in vivo (Kong et al., 1999a). 
Although still being debated, T cells are most likely not required for normal bone 
homeostasis (Kong et al., 1999b). However, systemic activation of T cells triggers bone 
loss thus, indicating a critical role of T cells in pathologic bone loss in vivo. Nowadays, 
many data strongly indicate that bone remodelling associated with systemic T cell 
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activation, viral infections, local bone inflammations and joint inflammation in arthritis 
is caused by RANKL-producing T cells (Theill et al., 2002).  
Since T cells produce INFγ, an inflammatory cytokine which suppresses 
osteoclastogenesis (Gowen and Mundy, 1986; Takayanagi et al., 2000) it has been 
unclear for a long time how T cells can mediate bone destruction (Sato et al., 2006). By 
which mechanism T cells enhance bone resporption has been clarified in 2006 with the 
identification of Th17 which link T cell activation to bone destruction (Sato et al., 
2006). Th17 cells are a specialized inflammatory subset of CD4+ T cells producing 
Interleukin 17 (IL 17) which has been reported to induce RANKL expression and 
osteclastogenesis in vitro (Sato et al., 2006). Moreover, IL 23, which is essential for 
expanding the population of Th17 cells is also critically involved in T-cell mediated 
enhancement of osteoclastogenesis (Sato et al., 2006). Thus, the IL 17-IL 23 axis plays 
a crucial role in autoimmune inflammation and in the development of rheumatoid 
arthritis by acting as an osteoclastogenic helper (Sato et al., 2006).  
Most recently our lab could show a novel and surprising new function of 
RANK/RANKL in the central nervous system (Hanada et al., 2009). RANK/RANKL 
are essential players in inflammatory fever response and in the regulation of female 
body temperature (Hanada et al., 2009). Mechanistically it appears that RANK/RANKL 
mediate fever in response to inflammation via the COX2-PGE(2)/EP3R pathway, 
whereas the regulation of female body temperature by RANK/RANKL is under the 
influence of sex hormones (Hanada et al., 2009). Since postmenopausal osteoporosis is 
often associated with hot flashes RANK and RANKL might now provide a plausible 
explanation for this symptom.  
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1.5. RANKL, RANK, OPG and the link to mammary gland formation  
Besides of the lack osteoclasts, lymph nodes and AIRE+ mTECs both RANK 
and RANKL knockout mice exhibt an additional phenotype. Both mouse strains fail to 
develop a functional lactating mammary gland during pregnancy resulting in the death 
of newborn pubs due to malnutrition (Fata et al., 2000). 
The development of the mammary gland proceeds in distinct steps in the context 
of sexual development and reproduction (Hennighausen and Robinson, 1998). Unlike 
most organs, mammary gland development predominantly takes place postpartum 
(Hennighausen and Robinson, 2001). In newborn mice, rudimentary mammary anlagen 
are present which elongate moderately into the mammary fat pad during prepuberty. At 
the onset of puberty progesterone, estrogens and growth hormones induce further ductal 
extension and branching (Hennighausen and Robinson, 2001). Furthermore, bulbous 
terminal end buds form at the end of the immature ducts and differentiate into quiescent 
alveolar buds (Oakes et al., 2008). During pregnancy, massive side branching, 
proliferation and differentiation of ductal and alveolar epithelilum results in the 
development of milk secreting lobuloalveolar structures. After pregnancy and lactation 
the lobuloalveolar buds undergo apoptosis and the mammary gland is remodelled back 
towards a virgin state, ready for the next pregnancy (Brisken et al., 1999; Hennighausen 
and Robinson, 2001) (Figure 3). 
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Figure 3. Stages in murine mammary gland development. Small mammary 
gland anlagen are established in the embryo. During puperty, mammary gland 
anlagen undergo only moderate proliferation.. During puperty, sex hormones 
induce further proliferation and extension of the mammary epithelial tree. At the 
onset of pregnancy pregnancy hormones such as progesterone and lactogenic 
hormones such as prolactin drive massive proliferation and differentiation to 
lobuloalveolar milk-secreting structures. After lactation involution resets the 
mammary gland into a virgin state. RANK and RANKL act during pregnancy, 
inducing the differentiation and proliferation of lobuloalveolar, milk-secreting 
structures. Figure adapted from (Hennighausen and Robinson, 2001). 
  
Mammary gland formation up to mid-pregnancy occurs normally in RANK-/- 
and RANKL-/- mice, the proliferation and terminal differentiation of alveolar buds to 
mature lobuloalveoli is completely arrested (Fata et al., 2000). Whereas RANKL 
expression in mammary epithelial cells is induced by pregnancy hormones, RANK is 
constitutively expressed on these cells (Fata et al., 2000). Importantly, RANK/RANKL 
signaling in the mammary gland is regulated in a very strict spatial and temporal 
manner. In a virgin gland RANKL mRNA is absent but increases gradually during 
pregnancy reaching a peak at P16.5 to then decrease again to low levels at the beginning 
of lactation (Gonzalez-Suarez et al., 2007). In contrast, RANK is constitutively 
expressed on mammary epithelial cells, though the expression is weak in virgin glands 
(Gonzalez-Suarez et al., 2007). RANK is also upregulated during pregnancy starting at 
P14.5. After reaching a maximum at day P15.5 in the alveolar buds, expression levels 
decrease again when the alveoli are about to secrete milk (Gonzalez-Suarez et al., 
2007). Importantly, RANK/RANKL mediates pregnancy induced mammary gland 
formation in an autocrine manner (Fata et al., 2000) and the transplantation of 
mammary glands RANK-/- or RANKL-/- into the cleared fat pads of wild type mice 
cannot rescue the phenotype (Fata et al., 2000). 
In 2001, it was reported that the subsequent activation of IKKα, NFκB and 
Cyclin D1 is crucial for RANKL-induced proliferation of the alveolar buds during 
pregnancy (Cao et al., 2001) (Figure 4). Indeed, IKKαAA/AA knockin females, in which 
the activation domain of IKKα is mutated, and CyclinD1-/- mice display a severe 
lactation defect which can be rescued by transgenic CyclinD1 expression. Further 
studies revealed that DNA-binding protein inhibitor 2 (Id2) is also a crucial 
RANK/RANKL downstream target involved in the proliferation and differentiation of 
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the mammary gland during pregnancy (Kim et al., 2006) (Figure 4). Of note, Id2-null 
mice also exhibit impaired lobuloalveolar development during pregnancy, though the 
mammary gland defects do not resemble those of CyclinD1-/- mice (Mori et al., 2003; 
Mori et al., 2000). In line with these phenotypic differences, the mammary gland defects 
of Id2-/- mice cannot be rescued through forced CyclinD1 expression (Mori et al., 2003). 
Thus, the question whether these two pathways act independent from one another still 
remains to be solved. 
 
 
 
 
 
 
 
 
 
 
FIGURE 4. RANK/RANKL signaling in mammary epithelial cells. 
RANK/RANKL signaling in mammary epithelial cells results in activation of the 
Id2 and NFκB pathways. RANKL expression in mammary epithelial cells triggers 
marked nuclear translocation of Id2 which is essential for cell cycle progression 
through the inhibition of p21 expression. Upon RANK activation IKKα induces 
the nuclear translocation of NFκB dimers by mediating the degradation of the 
IkBα.  In the nucleus, NFkB leads to the expression of the cell cycle regulator 
Cyclin D1. All indicated pathways have been shown to be important by genetic 
experiments (Cao et al., 2001; Kim et al., 2006). 
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1.6. Sex hormones in mammary gland development and tumorigenesis 
RANKL expression in mammary epithelial cells is induced by the sex and 
pregnancy hormones Progesterone, Prolactin (PRL) and Parathyroid hormone-related 
protein (PTHrP) (Fata et al., 2000). The steroid hormone Progesterone plays a pivotal 
role in all aspects of female reproductive activity. Its physiological effects are mediated 
by the progesterone receptor (PR) which belongs to the nuclear receptor superfamily 
(Conneely et al., 2003a). Upon binding of progesterone a PR-ligand complex is formed 
followed by translocation to the nucleus (Conneely et al., 2003a). In mammals there are 
two structurally and functionally distinct nuclear receptors referred to as PR-A and PR-
B. Besides female infertility and other reproductive abnormalities, mice lacking both 
isoforms of the progesterone receptor (PRKO) display severe defects in mammary gland 
development during pregnancy (Conneely et al., 2003a). In particular, PRBKO but not 
PRAKO knockout mice fail to undergo pregnancy induced ductal side-branching and 
lobuloalveolargenesis. Intriguingly, this defect mainly results from dramatically reduced 
RANKL levels (Mulac-Jericevic et al., 2003), thus strongly emphasizing a tight 
connection between RANK/RANKL and progesterone.  
Progesterone has not only been associated with normal breast development but 
also with an increased risk of developing breast cancer. Both human and mouse data 
support a critical role for progesterone signaling in mammary carcinogenesis (Conneely 
et al., 2003b; Ross et al., 2000; Sitruk-Ware, 2002). Whereas progesterone is known to 
decrease the risk of developing endometrial cancer (Sitruk-Ware, 2002), overexposure 
to progesterone is a known risk factor for breast cancer (Mc Cormack et al., 2007). As 
reported by the Million women and the Womens Health Initiative studies, women 
receiving a combined HRT of progesterone and estrogen were 2 fold more likely to 
develop breast cancer compared to women receiving estrogen alone (Beral, 2003; 
Rossouw et al., 2002). Of note, it has also been reported that pregnancy and low-dose 
estrogen and progesterone treatment prevents chemically induced carcinogenesis (Jemal 
et al., 2009). However, the exact regulatory mechanisms by which progesterone is 
linked to mammary tumorigenesis are still unclear.  
The lactogenic hormone PRL can also induce RANKL expression in the 
mammary gland (Fata et al., 2000). PRL is not only closely related to mammary gland 
development during pregnancy but also has been associated with mammary 
tumorigenesis (Llovera et al., 2000; Oakes et al., 2007). PRL is produced by the 
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pituitary gland but can also be secreted locally by mammary epithelial cells (Oakes et 
al., 2008). The prolactin receptor (PRLR) belongs to the superfamily of class I cytokine 
receptors. Upon prolactin binding PRLR dimerizes and activates a variety of 
downstream signaling cascades (Oakes et al., 2008). For instance, activation of PRLR 
results in the phosphorylation and activation of the Janus kinase 2 (JAK2) which is 
followed by recruitment and activation of STAT5 (Signal transducer and activator of 
transcription 5). Phosphorylated and dimerized STAT5 then translocates to the nucleus 
where it activates the transcription of genes required for alveolar morphogenesis (Oakes 
et al., 2008).  
PRL and PRLR knockout mice exhibit a defect in mammary gland development 
already prior to pregnancy (Brisken et al., 1999, Ormandy, 1997 #138). In wild type 
animals the mammary gland undergoes ductal side branching and differentiation to 
quiescent alveolar buds as soon as the terminal end buds reach the periphery of the fat 
pad during puperty. This process is completely arrested in PRL-/- and PRLR-/- mice 
(Horseman et al., 1997). Similar defects in ductal brancing and differentiation of 
terminal end buds can also be observed in STAT5 knockout mice (Liu et al., 1998). As 
PRLR-/- mice are infertile, mammary gland development during pregnancy could not be 
assessed in knockout females but only in heterozygous PRLR+/- mice (Ormandy et al., 
1997). These heterozygous PRLR+/- mice undergo normal mammary gland development 
up to mid pregnancy but then exhibit impaired lobuloalveoar development (Brisken et 
al., 1999). Thus, the phenotype of PRLR+/- mice is similar to the phenotype observed in 
RANK, RANKL and PR-knock out mice suggesting a potential link between these 
pathways. 
In women, elevated serum PRL levels correlate with a twofold increase in the 
risk of developing breast cancer, and especially of invasive ER-α positive and PR-
positive breast cancers (Oakes et al., 2007, Arendt, 2009). Overexpression of PRL in 
mice leads to the development of mammary cancer indicating that high levels of PRL 
alone are sufficient to induce mammary tumors (Oakes et al., 2007). Further, PRLR-
deficient mice display delayed tumor onset in response to oncogenic stimuli (Oakes et 
al., 2007). PRL modulates carcinogenesis within the mammary epithelium directly as 
well as through the actions of estrogen and progesterone (Oakes et al., 2007). 
Mechanistically, PRL stimulation induces increased proliferation and CyclinD1 
expression predominantly mediated by the JAK2/STAT5 signalling pathway (Schroeder 
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et al., 2002). Thus, the induction of Cyclin D1 expression by PRL suggests another 
potential link between RANK/RANKL and PRL-signaling.  
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1.8. Project outline 
RANK-RANKL signaling is known as a very important survival pathway in 
mammary gland development during pregnancy. In addition, RANKL expression can be 
induced by the sex hormones progesterone, prolactin and PTHrP which are also known 
to be involved in mammary tumorigenesis, suggesting a plausible role for RANK-
RANKL signaling in breast cancer development. The aim of my study therefore, was to 
investigate the role of RANK-RANKL and its downstream targets in hormonal driven 
primary breast cancer in mice. In order to do this I specifically inactivated the RANKL 
receptor RANK in mammary epithelial cells (RANK∆mam). Intriguingly, RANK∆mam 
mice develop breast cancer significantly later than wild type littermate controls in 
response to progesterone/DMBA treatment. Furthermore, by generating IKKα∆mam, 
TRAF6∆mam and NFATc1∆mam mice, I was able to show that whereas these effectors are 
required for RANK-RANKL effects on osteoclastogenesis, only IKKα appears to be 
critical for the regulation of breast cancer onset. Thus, our findings provide the first 
direct evidence that RANK-RANKL, through activation of NFκB signaling, controls 
development of hormone-dependent breast cancer. 
 
 
 
 
 
 
 
 
 
 
 

2. Results 
In addition to our first knockout experiments (Fata et al., 2000), two 
overexpression-studies have suggested a potential role of RANK/RANKL in mammary 
epithelial cell growth. Gonzalez-Suarez et al. reported that MMTV-driven expression of 
RANK triggers massive proliferation of the mammary epithelium upon pregnancy 
(Gonzalez-Suarez et al., 2007). Moreover, mammary epithelial cells derived from these 
transgenic mice exhibit increased proliferation when put in 3-dimensional culture 
(Gonzalez-Suarez et al., 2007). 
Similarly, Fernandez-Valdivia et al. could show that nulliparous MMTV-
RANKL transgenic mice develop mammary hyperplasia with age (Fernandez-Valdivia 
et al., 2009). Importantly, sex hormones such as prolactin and progesterone which are 
crucial in RANKL-induced mammary gland development during pregnancy (Fata et al., 
2000) are also related to breast cancer (Llovera et al., 2000; Oakes et al., 2007). Thus, 
we speculated that RANK/RANKL is involved in hormone-driven mammary 
tumorigenesis.  
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2.1. MPA/DMBA treatment leads to the induction of mammary tumors in wildtype 
mice 
Synthetic progesterone derivatives (progestins) such as medroxyprogesterone 
acetate (MPA) are used in millions of women for hormonal replacement therapy (HRT) 
and contraceptives (Rossouw et al., 2002; Schwallie and Mohberg, 1977). A positive 
effect of using progesterone is that it decreases the risk of developing estrogen-driven 
endometrial cancer (Beral et al., 2005). But progestins are also known to be critically 
involved in mammary tumorigenesis (Mc Cormack et al., 2007). Moreover, according 
to the Women`s Health Initiative (WHI) and the Million Women Study the use of 
progestins, in particular MPA appears to markedly increase the risk of developing breast 
cancer (Beral, 2003; Rossouw et al., 2002). 
A method to model progestin-driven breast cancer in female mice has been 
described (Aldaz et al., 1996, Cao et al., 2007). In this model the subcutanous 
implantation of slow release MPA pellets accelerates the development and increases the 
incidence of short latency mammary tumors in response to the DNA damaging 
carcinogen dimethylbenz(a)anthracene (DMBA). Of note, the course of the developing 
mammary tumors resembles that of human breast cancers (Escrich, 1987a; Escrich, 
1987b). 
To set up the protocol, we implanted MPA pellets (50mg 90-day release MPA 
pellets, Innovative Research of America NP-161) subcutaneously in the right flanks of 6 
week old nulliparous BalbC wildtype mice followed by oral gavage of a DMBA-
containing solution (Figure 5a). All female mice treated according to the scheme 
developed mammary tumors with 100% penetrance. The median tumor free survival is 
about 10 days after the last DMBA treatment (Figure 5b). Thus, I was able to 
successfully establish this progestin-driven breast cancer model in our laboratory. 
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Figure 5. MPA/DMBA treatment induces mammary tumors in wildtype 
mice. a, MPA/DMBA carcinogenesis scheme. Nulliparous, six-week old female 
mice were s.c. implanted with slow release Medroxyprogesterone acetate (MPA) 
pellets and treated orally with Dimethylbenz(a)anthracene DMBA 6 times 
throughout 8 weeks (W) as indicated. b, Onset of palpable tumors in wild type 
mice (n=10) treated with MPA and DMBA as indicated in Fig. 5a. Data are shown 
as percentage of tumor free mice after the last DMBA challenge. 
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2.2. In vivo progestine administration leads to massive RANKL expression via the 
Prolactin receptor  
The RANK/RANKL system in the mammary gland is tightly linked to hormonal 
regulation and previously it has been shown that RANKL expression can be induced by 
progesterone stimulation in nulliparous female mice (Fata et al., 2000). In order to 
examine whether the synthetic progesterone-derivative MPA also affects RANKL 
expression in the mammary glands we implanted MPA pellets into the right flanks of 6 
week old estrus-synchronized female wild type mice. We observed a mareked 
upregulation of RANKL expression in the serum (Figure 6a). Moreover, in isolated 
mammary epithelial cells RANKL mRNA was upregulated up to 2000 times three days 
and six days after MPA stimulation (Figure 6b). Interestingly, we did not detect an 
increase in expression of the 45 kDa membrane bound RANKL isoform but we 
observed elevated levels of the 19kDa soluble form of RANKL (Figure 6c), which can 
be derived either from alternative splicing or cleavage of the membrane bound form 
(Ikeda et al., 2001). Of note, neither sham-operated nor DMBA treated mice exhibited 
an increase of RANKL mRNA levels in isolated mammary gland epithelial cells (Figure 
6d). Thus, MPA treatment results in a systemic and mammary gland specific 
upregulation of RANKL expression.  
Recently, it has been reported that prolactin can directly induce RANKL 
expression via the JAK2/STAT5 pathway (Srivastava et al., 2003). Interestingly, MPA 
can also induce the transcription of prolactin (Reis et al., 1999) as well as the prolactin 
receptor in breast cancer cells (Chaudhury et al., 1977; Ormandy et al., 1992). Therefore 
we speculated that MPA induces RANKL expression in mammary epithelial cells via 
the prolactin receptor. Analysis of prolactin receptor knockout mice (Ormandy et al., 
1997) revealed that RANKL protein expression was not induced three days after MPA 
pellet implantation whereas in littermate controls we observed a significant upregulation 
of RANKL expression upon MPA stimulation (Figure 6e). Intriguingly, whereas 
RANKL protein was completely undetectable in prolactin receptor mutants we could 
still observe an increase of RANKL mRNA in isolated mammary epithelial cells 
(Figure 6f). Thus, one could speculate that the absence of the PRL not only affects 
RANKL expression but could also interferes with RANKL mRNA stability. Taken 
together, these results suggest that MPA triggers massive RANKL expression in 
mammary epithelial cells, at least in part, via the prolactin receptor in vivo.  
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 Figure 6. The progesterone-derivative MPA triggers in vivo RANKL 
expression via the prolactin system. a-d, Induction of RANKL expression by the 
progesterone-derivative MPA. Nulliparous wild type females were subcutaneously 
implanted with slow-release MPA pellets or treated with surgery sham. a, 
Systemic RANKL levels were determined in serum 3 days after MPA pellet 
implantation by ELISA. Data are shown as pg RANKL/ml serum (mean values, 
+/- sem; n=3 mice per group). ** P > 0.005 (Student`s t-test). b, Total mRNA was 
isolated from purified mammary epithelial cells 3 days after MPA implantation. 
RANKL mRNA was determined by qRT-PCR relative to β-actin levels. Data are 
shown as fold change compared to sham treatment (mean values, +/- sem; n=3 
mice per group). *** P > 0.0005 (Student`s t-test). c, Expression of 
transmembrane (tm) and soluble (s) RANKL protein was assayed on isolated 
mammary gland epithelial cells by Western blot 3 and 6 days after MPA pellet 
implantation or sham surgery. β-actin is shown as a loading control. Recombinant 
sRANKL and tmRANKL protein are shown for molecular size comparison in the 
right panels. Data are representative of 8 animals tested. d, MPA but not oil-
vehicle, DMBA or surgery sham induces RANKL expression in mammary 
epithelial cells. Total mRNA was isolated from purified mammary epithelial cells 
3 days after oil-gavage, DMBA-treatment, surgery sham and MPA-implantation. 
RANKL mRNA was determined by qPCR relative to β-actin levels. Data are 
shown as fold change compared to sham treatment +/- sem (n=3 mice per group) 
e, Induction of soluble RANKL protein assayed on isolated mammary gland 
epithelial cells in control, but not in prolactin receptor mutant (PRLR KO) 
females on day 3 after s.c. MPA implantation. Mammary glands from sham 
operated control littermates and PRL-R KO females are shown as controls (n=3 
animals per group) f, Total mRNA was purified from isolated mammary epithelial 
cells of PRLR KO mice and control females 3 days after MPA pellet implantation 
and sham-surgery. RANKL expression relative to β-actin levels was determined 
by qRT-PCR. Data are shown as fold change compared to sham treatment +/- sem 
(n=3 mice per group). * P > 0.05 (Student`s t-test). 
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2.3. MPA induced RANKL expression triggers massive proliferation of mammary 
epithelial cells in vivo 
During pregnancy RANKL expression induces proliferation of mammary 
epithelial cells (Fata et al., 2000). Therefore we examined whether MPA-induced 
RANKL expression can also trigger proliferation of mammary epithelial cells in vivo.  
Using Ki67 as a proliferation marker we determined proliferation rates in nulliparous 
female mice in which we have deleted RANK specifically in mammary epithelial cells 
(RANK∆mam) and littermate controls upon MPA-treatment. The generation of 
RANK∆mam mutant mice will be discussed in chapter 2.4. Indeed, three days after MPA 
implantation we could detect a strong induction of proliferation in the mammary glands 
of nulliparous control females as defined by Ki67+ cells (Figures 7a, b).  
In RANK∆mam nulliparous female mice induction of proliferation of mammary 
epithelial cells in response to MPA was significantly lower than in control mice 
(Figures 7a, b). Up to 80% of acini of control mice showed signs of medium to high 
proliferation. Intriguingly, in more than 60 % of all acini of RANK∆mam females 
analyzed we observed only very few proliferating cells (Figure 7c). The slight induction 
of proliferation in RANK∆mam mutant mice could be explained with incomplete RANK-
deletion and proliferation of remaining wildtype cells. Of note, proliferation was not 
induced in sham operated female mice (Figure 7d). Importantly, since proliferation in 
mammary glands varies during the course of the estrus (Fata et al., 2001) all mice used 
in this experiment were synchronized for the estrus cycle. To test whether MPA induced 
RANKL can directly induce proliferation in mammary epithelial cells we next injected 
RANKL i.p. into control and RANK∆mam mice (5µg/mouse). As expected, we could 
observe massive proliferation in mammary epithelial cells of control mice whereas 
RANK∆mam female mice showed significantly reduced induction of proliferation in 
response to RANKL (Figure 7e). Thus, we conclude that the massive proliferation of 
mammary epithelial cells upon MPA stimulation is largely controlled by 
RANK/RANKL signaling.  
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 Figure 7. MPA-induced RANKL expression triggers massive proliferation 
of mammary epithelial cells in vivo. a, Epithelial proliferation was detected by in 
situ Ki67 staining of mammary gland sections of estrus-synchronized RANK∆mam 
females and control mice 3 days after MPA treatment. b, Quantification of Ki67+ 
cells shows the relative changes in proliferation of mammary epithelial cells three 
days after MPA treatment. MPA treated mice were compared to sham-operated 
females of the respective genotype. Data are shown as mean value +/- sem, n=3 
mice per genotype. ** P > 0.005 (Student’s t-test). c, Quantification of Ki67+ 
mammary epithelial cells after 3 days of MPA treatment, n=3 mice per genotype. 
* P > 0,05; ** P > 0.005; *** P > 0.001 (Student`s t-test) d, Quantification of Ki67+ 
mammary epithelial cells of oestrus-cycle synchronized wild type and RANK∆mam 
females 3 days after surgery sham, n=3 mice per genotype. Data in c, and d, are 
shown as percentage of acini/ducts with low (<20% of epithelial cells per 
acinus/duct are Ki67+), medium (20-80% of epithelial cells per acinus/duct are 
Ki67+) and high (>80% of epithelial cells per acinus/duct are Ki67+) numbers of 
proliferating cells +/- sem. e; Epithelial proliferation after i.p. RANKL injection 
(5mg/mouse); control females were injected with PBS. Data are shown as relative 
fold change of Ki67+ cells 3 days after RANKL/PBS injection, mean values +/- 
sem. n = 3 mice per genotype. ** P > 0.005; (Student’s t-test). For b, c, d and e at 
least 1000 mammary gland epithelial cells were counted per mouse. 
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2.4. Generation of RANK∆mam mice  
In order to reveal the potential functions of RANK/RANKL in the development 
of mammary tumors we generated a mouse line in which the receptor of RANKL, 
RANK, is specifically deleted in mammary epithelial cells. To this aim, we crossed 
mice harboring a conditional RANK allele to a MMTV-cre deleter line which mediates 
the recombination of the conditional allele in mammary epithelial cells (Wagner et al., 
2001) (Figure 8a). These mice are hereafter termed as RANK∆mam. RANK∆mam mice 
appear healthy and are born at normal Mendelian ratios. They don’t display impaired 
breast development during puperty (Figure 8b). Moreover, lymphnode development is 
normal. RANKfloxed mice have been recently published by our group and reproduce all 
phenotypes of RANK full body knockout mice when crossed to the ubiquitous deleter 
line β-actin-cre (Lewandoski et al., 1997). Thus, we have generated RANK∆mam mice 
that delete RANK in mammary epithelial cells. 
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Figure 8. Generation of RANK∆mam knockout mice. a, Gene targeting strategy for 
the generation of the conditional RANK mutant allele. Breeding with MMTV-Cre mice 
specifically induces deletion of RANK exons 3 and 4 in mammary epithelial cells. 
Genotyping primers are indicated as red arrowheads (P1, P2 and P3). Primers P1 and P2 
detect the wild type allele and the floxed allele, respectively. Primers P1 and P3 detect the 
knockout (KO) allele. b, Nulliparous RANK∆mam female mice exhibit normal mammary 
gland development. Whole mount staining (upper panels) and H&E analysis (lower 
panels) of mammary glands of control and RANK∆mam females showing normal ductal 
side branching and apparently normal ductal/epithelial structures.  
 

2.5. Tissue specific inactivation of RANK in mammary epithelial cells results in a 
delayed onset of primary breast cancer 
We next induced progestin-driven breast cancer in 6 week old RANK∆mam 
females and littermate controls according to the scheme described in Figure 5a. Control 
mice rapidly developed mammary tumors in response to MPA/DMBA treatment. 
Intriguingly, RANK∆mam female mice exhibited a marked delay in the onset of 
MPA/DMBA-induced palpable mammary tumors (Figure 9a). Only one RANK∆mam 
female exhibited a palpable tumor at an early time point when all control mice had 
already developed tumors. The median time until the first detection of palpable tumors 
was 7 days after last DMBA treatment in control mice and 27 days in RANK∆mam 
females. Of note, the tumor onset was comparable between MMTV-cre-positive and 
MMTV-cre-negative control mice (Figure 9b). Histological analysis revealed that most 
of the occurring tumors in both RANK∆mam and littermate controls are typical ductal 
adenocarcinomas (Figure 9c). The absence of RANK in tumors that developed in 
RANK∆mam females was confirmed by Southern blotting (Figure 9d). Some residual 
wild type bands which we could still observe may be explained by the presence of other 
cell types like stromal cells and infiltrates and/or escaper cells. These data show that 
deletion of RANK in mammary epithelial cells significantly delays the onset of 
progestin-driven breast cancer. 
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Figure 9. RANK controls the incidence and onset of progestin-driven 
mammary cancer. a, RANK∆mam females (n=8) exhibited a markedly delayed onset 
of mammary tumors in response to MPA/DMBA callenge compared to age-
matched littermate control females (n=12). b, Tumor onset in response to 
MPA/DMBA challenge is comparable between cre-positve (n=7) and cre-negative 
(n=5) control mice. Mice in a, and b, were treated with MPA pellets and DMBA as 
indicated in Figure 5a. Mammary tumor onset was determined by palpation. Data 
are shown as percentage of tumor free mice after the last DMBA challenge. c, 
H&E staining of representative histological sections of mammary tumors isolated 
from control littermate and RANK∆mam females 56 days after the last DMBA 
treatment showed typical features of adenocarcinomas. d, Southern blot analysis 
of mammary tumors derived from RANK∆mam and control females for 
confirmation of deletion in tumors. Genomic DNA was digested with BamHI and 
SphI. The floxed/+ and the deleted (∆) alleles are indicated by arrowheads.  
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2.6. The numbers of carcinomas in situ and invasive carcinomas is 
decreased in RANK∆mam females 
Further analysis of mammary tumor incidence in response to MPA/DMBA at 
early stages emphasized the critical role of RANK/RANKL in breast cancer onset. All 
RANK expressing control females sacrificed only seven days after the last DMBA 
treatment already exhibited multiple highly proliferative in situ carcinomas and even 
invasive mammary tumors. By contrast, in RANK∆mam we detected only very few 
carcinomas in situ and never any invasive tumor one week after the last DMBA 
challenge (Figure 10a). Three weeks after last DMBA treatment the number of 
carcinomas in situ was similar between RANK∆mam females and control littermates 
however the incidence of invasive carcinomas in controls was significantly increased in 
the littermate controls (Figure 10b). Thus, the development of carcinoma in situ and 
invasive carcinomas in response to MPA/DMBA is delayed in RANK∆mam females. 
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 Figure 10. Incidence of carcinomas in situ and invasive carcinomas is 
reduced in RANK∆mam females 7 and 22 days after final DMBA treatment. a and b, 
Numbers of carcinomas in situ and invasive mammary cancers in control and 
RANK∆mam females on day 7 (a) and day 22 (b) after the final DMBA treatment. 
Data are shown as mean values per mouse +/- sem (n= 3 mice per genotype). All 10 
mammary glands were analysed for each mouse. * P > 0.05 (Student’s t-test). The 
upper panels show H&E staining of representative histological sections. The lower 
panels represent immunostaining for the proliferation marker Ki67. Control 
females display typical invasive adenocarcinomas on days 7 and 22. For 
RANK∆mam female mice, normal acinar morphology (day 7) and a carcinoma in 
situ (day 22) are shown.  
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2.7. Neither RANK Mx-Cre nor RANK∆mam NeuT-positve female mice display a 
delayed onset of breast cancer 
It is known that the MMTV-cre transgene is not only expressed and active in 
mammary epithelial cells but also in other secretory organs as well as in B cells and T 
cells and in the female germline (Wagner et al., 2001). To rule out any contributions of 
deletion in other organs of RANK∆mam mice, we next examined MPA/DMBA-induced 
tumor onset in RANK Mx-cre mice. Importantly, Mx-cre mediated deletion of RANK 
in liver, heart, muscle and the haematopoietic system (Figure 11a) did not delay tumor 
onset (Figure 11b). This suggests that cell-autonomous RANK/RANKL signaling is 
critical for early events of malignant transformation in mammary epithelial cells.  
Furthermore, one of the major genetic alternations observed in human mammary 
tumors is the mutation of the human epidermal growth factor 2 (ErbB2) which is also 
known under the acronyms Neu and Her2 (Ursini-Siegel et al., 2007). ErbB2-dependent 
breast cancer can be modeled with transgenic mice overexpressing an activated form of 
the Neu-oncogene (Ursini-Siegel et al., 2007). In order to investigate the role of RANK 
and RANKL in this genetical mammary tumor model we crossed our RANKfloxed mice 
to a transgenic NeuT line. Interestingly, MMTV-driven deletion of RANK did not alter 
tumor incidence in the NeuT-positive female mice (Figure 11c). The deletion of RANK 
in tumors derived from RANK∆mam NeuT-positive female mice was confirmed by 
Southern blotting (Figure 11d). Thus these results indicate that RANK/RANKL is a 
critical mediator of progestin-induced breast cancer in vivo.  
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Figure 11. Neither RANK Mx-Cre nor RANK∆mam NeuT-positive female 
mice display a delayed onset of breast cancer. a, Southern blot analysis on various 
tissues of the RANKfloxed allele before (fl/+) and after Mx-Cre-induced deletion 
(fl/∆). Mx-Cre mediated deletion was induced by 4 consecutive injections of poly 
I:C over the course of 8 days. Genomic DNA was digested with BamHI and Sph1. 
Floxed/+ and delta (∆) alleles are indicated with arrowheads. A BAC vector was 
loaded as a control for the floxed and + alleles. b, Survival of Mx-Cre RANKfl/∆ 
females (n=4) and age-matched littermate controls (n=6) after MPA/DMBA 
challenge as indicated in Figure 5a. Data are shown as percentage of tumor free 
mice after last DMBA treatment. c, Onset of palpable tumors in RANK∆mam NeuT-
positive females and littermate controls. Data are shown as percent of tumor free 
mice after birth. d, Southern blot analysis of tumors derived from RANK∆mam 
NeuT-positive female mice (n=13) and RANK+/∆ NeuT-positive controls (n=14) 
confirming RANK deletion. Genomic DNA was digested with BamHI and Sph1. 
Floxed/+ and delta (∆) alleles are indicated with arrowheads. 
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2.8. RANK/RANKL activate the NFκB pathway in primary mammary epithelial 
and breast cancer cells  
Previously it has been shown that RANK/RANKL signals proliferation and 
differentiation in the mammary gland via the the Id2 pathway (Kim et al., 2006) and the 
IKKα – NFκB – CyclinD1 axis (Cao et al., 2001). To analyze the activation status of 
the Id2 and the NFκB pathways in MPA/DMBA-induced mammary adenocarcinomas 
we pooled tumors derived from RANK∆mam females and control littermates, 
respectively. By Western blotting we found that tumors which grew out in RANK∆mam 
female mice exhibited impaired NFκB signaling indicated by increased protein levels of 
the inhibitor of NFκB, IκB, decreased p65 NFκB phosphorylation (Figure 12a) and 
reduced mRNA levels of the NFκB target Cyclin D1. Moreover, we could also detect an 
increase of p21 mRNA in RANK∆mam tumors (Figure 12b). p21 is a negative regulator 
of cell cycle progression (Gartel et al., 1996) being transcriptionally suppressed by the 
Id2 pathway (Kim et al., 2006). Furthermore, RANKL stimulation of primary mouse 
mammary epithelial cells also resulted in upregulation of NFκB signaling as indicated 
by elevated p65 NFκB and IkBα phosphorylation (Figure 12c). We also observed 
induction of the NFκB pathway in the human breast tumor cell line SKB3 in response to 
RANKL stimulation (Figure 12d). Thus, RANK/RANKL induces NFκB as well as Id2 
signaling in normal and transformed mammary epithelial cells. 
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Figure 12. RANK/RANKL activates the NFκB pathway in mammary 
epithelial cells and breast cancer cells. a, NFκB pathway activation status in 
pooled late stage tumors derived from RANK∆mam females and control littermates. 
Tumors isolated from RANK∆mam females (n=4) and tumors from control mice 
(n=4) were pooled and levels of IKKα, β, γ, phosphorylated (P) p65 NFκB, total 
p65 NFκB, phosphorylated (P) IκBα and total IκBα were assessed by Western 
blotting.  b, Relative expression levels of RANK, CyclinD1 and p21 were 
determined by qRT-PCR on total mRNA isolated from tumors of RANK∆mam 
females and control littermates. Data are shown as mean values +/- sem (n=4 for 
each genotype). * P > 0.05 (Student’s t-test). c, Western blotting on total protein 
extracts of mammary epithelial cells for phosphorylated (P) IKKα, total IKKα, 
phosphorylated (P) p65 NFκB, total p65 NFκB, phosphorylated (P) IκBα and total 
IκBα untreated (0 min) and in response to RANKL stimulation (1µg/ml) after 15, 
60 and 120 minutes. d, Western blotting for phosphorylated (P) p65 NFκB, total 
p65 NFκB, phoshphorylated (P) IκBα and total IκBα in untreated (0 min) SKB3 
human breast cancer cells and SKB3 cells in response to RANKL stimulation 
(1µg/ml) after 5, 15, 30 and 60 minutes.  
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2.9. Mammary epithelial cell specific inactivation of IKKα but not TRAF6 and 
NFATc1 delays the onset of primary breast cancer 
RANK/RANKL induced osteoclast differentiation and activation essentially 
requires NFκB signaling (Franzoso et al., 1997; Iotsova et al., 1997) and TRAF6 which 
is the major adaptor molecule for NFκB activation downstream of RANK/RANKL 
(Darnay et al., 1998; Darnay et al., 1999). Moreover, RANK/RANKL mediated 
osteoclastogenesis also requires the calcineurin-NFATc1 signaling pathway 
(Takayanagi et al., 2002a). Importantly, NFATc1 can also be regulated by the Id2 
pathway (Lee et al., 2006). To assess whether these key-downstream pathways of 
RANK/RANKL are also important in tumor onset of progestin-driven mammary tumors 
we generated MMTV-Cre Nfatc1floxed/floxed (NFATc1∆mam), Traf6floxed/floxed (TRAF6∆mam) 
and Ikkαfloxed/floxed (IKKα∆mam) conditional knockout mice in which NFATc1, TRAF6 
and IKKα are specifically deleted in mammary epithelial cells. All mutant mouse lines 
were born healthy. Interestingly, IKKα∆mam mice exhibited a markedly delayed onset of 
mammary tumors in response to MPA/DMBA treatment (Figure 13a). The median time 
of palpable mammary tumor onset in littermate controls was 10 days and 24 days in 
IKKα∆mam mutant mice. Deletion of IKKα in tumors derived from IKKα∆mam mice was 
confirmed by Western blotting (Figure 13b). Analysis of pooled tumors from IKKα∆mam 
mice confirmed downregulation of the NFκB pathway. The expression of IKKβ and 
IKKγ is not changed (Figure 13b). Of note, our results are supported by the previous 
finding that mutation of the IKKα kinase domain in IKKαA/A knock-in mice results in a 
delayed onset in both the MPA/DMBA and NeuT mammary cancer models (Cao et al., 
2007). Surprisingly, neither TRAF6∆mam nor NFATc1∆mam mutant female mice exhibited 
delayed onset of mammary tumors in response to MPA/DMBA (Figure 13c, d). These 
results indicate that RANK/RANKL in mammary glands controls the onset of 
mammary tumors in mice at least in part by activating the NFκB pathway. 
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Figure 13. Deletion of IKKα in mammary epithelial cells delays the onset of 
mammary tumors in response to MPA/DMBA. a, c, and d, Onset of palpable 
mammary tumors in IKKα∆mam (a), NFATc1∆mam (c) and TRAF6∆mam females (d) 
and age-matched littermate controls in response to MPA/DMBA treatment as 
indicated in Figure 5a. Data are shown as percentage of tumor free mice after last 
DMBA treatment. (IKKα∆mam n=9, IKKα control n=11; TRAF6∆mam n=7, TRAF6 
control n=10; NFATc1∆mam n=6, NFATc1 control n=14) b, Western blotting for 
IKKα, β, γ, phosphorylated (P) p65 NFκB, total p65 NFκB, phosphorylated (P) 
IκBα and total IκBα on pooled tumors isolated from IKKα∆mam and control 
females, n=4 mice per genotype.  
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2.10. RANK/RANKL protects mammary epithelial cells form γ-irradiation induced 
cell death 
Apoptosis in response to genotoxic stress is essential for the survival of an 
organism (Jackson and Bartek, 2009). A failure in activating the death machinery upon 
severe DNA damage has fatal consequences and provides a prerequisite for the 
initiation of cancer (Hanahan and Weinberg, 2000). The DNA damaging agent DMBA 
which we used in our progestin-driven cancer model induces genotoxic stress by 
randomly introducing a large number of point mutations (Aldaz et al., 1996). As 
RANK∆mam female mice exhibited a markedly delay in tumor onset in response to 
MPA/DMBA challenge we were wondering whether RANK/RANKL also protects 
mammary epithelial cells from genotoxic stress-induced programmed cell death. Thus, 
we performed subcutanous implantation of MPA pellets in RANK∆mam females and 
control mice in order to stimulate RANKL expression. Using active caspase3 as a 
marker for cell death (Mazumder et al., 2008) we then analyzed γ-irradiation induced 
apoptosis in the mammary glands in vivo. γ-irradiation triggered a marked increase of 
apoptotic mammary epithelial cells in both RANK∆mam and control females. 
Intriguingly, γ-irradiation after three days of MPA-stimulation resulted in a significantly 
reduced number of apoptotic mammary epithelial cells in control females compared to 
MPA-treated RANK∆mam mice (Figures 14a, b). Therefore we conclude that MPA 
markedly protects from γ-irradiation-induced cell death dependent on RANKL 
expression. 
Figure 14. MPA-induced RANKL expression protects mammary epithelial 
cells of γ-irradiation induced cell death. a, Immunostaining of mammary glands 
sections with the apoptotic marker active caspase3. Arrows indicate apoptotic 
mammary epithelial cells in sham-operated (upper panels) and MPA treated 
(lower panels) RANK∆mam females and littermate controls isolated 6 hours after γ-
irradiation (5 Gray). b, Quantification of active caspase3 positive nuclei of 
mammary epithelial cells of sham-operated, MPA-treated, γ-irradiated and MPA-
treated plus γ-irradiated RANK∆mam females and littermate controls 6 hours after 
γ-irradiation. A minimum of 5000 nuclei was counted for each mouse. Results 
shown are mean values +/- sem, n = 3 mice per group. * P > 0.05; ** P > 0.02 
(Student’s t-test). 
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2.11. Generation and characterization of MMTV-RIC mice 
Mice overexpressing RANK specifically in mammary epithelial cells display a 
severe lactation defect due to impaired lobuloalevolar differentiation during pregnancy 
(Gonzalez-Suarez et al., 2007). Moreover, in vitro culture of mammary epithelial cells 
isolated from these mice hyperproliferate in response to RANKL stimulation 
(Gonzalez-Suarez et al., 2007). Now we report, that deletion of RANK in mammary 
epithelial cells of female mice results in a significant delay of mammary tumor onset in 
response to MPA/DMBA. Taken together, all these results clearly emphasize a critical 
role for RANK/RANKL in hormone driven mammary carcinogenesis. Therefore we 
decided to generate new transgenic mouse lines which overexpress RANK and cre-
recombinase under the control of the mouse mammary tumor virus (MMTV) long 
terminal repeat (LTR) (MMTV-RIC-Ires-CRE) (Figure 15a) in order to further dissect 
the RANK/RANKL downstream signaling pathways in mammary tumorigenesis. 
In total 6 founder lines harboring the MMTV-RANK-Ires-CRE transgene were 
generated by pronuclear injection. Ires is an internal risbome entry site (Ires) which 
allows the 5’-cap independent initiation of Cre-expression (Hellen and Sarnow, 2001). 
These mice will hereafter be termed as MMTV-RIC lines 1 to 6. 5 out of the 6 MMTV-
RIC lines successfully transmitted the transgene to their progeny, thus confirming 
germline transmission. In order to verify transgene expression we isolated total RNA of 
mammary epithelial cells from offsprings of lines 2, 3 and 4. All lines analyzed express 
the MMTV-RIC mRNA as shown by Cre-PCR on total cDNA isolated from mammary 
epithelial cells (Figure 15b). Furthermore, we confirmed by qRT-PCR that carriers of 
line 3 express the highest levels of the transgene in isolated mammary epithelial cells 
(Figure 15c). We next determined the tissue specificity of transgene expression. qRT-
PCR revealed that high levels of transgene mRNA are expressed in mammary epithelial 
cells, spleen, liver and lung while moderate MMTV-RIC expression was detected in the 
ovaries. Surprisingly, in line 3 the thymus was the site of highest transgene mRNA 
expression (Figure 15d).  
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 Figure 15. Generation of MMTV-RIC transgenic mice. a, Schematic of the 
linearized MMTV-RANK-Ires-Cre construct used for pronuclear injection. b, 
PCR on total mRNA isolated from mammary epithelial cells of offsprings from 
MMTV-RIC lines 2, 3 and 4. Lane 1 = cDNA MMTV-RIC. Lane 2 = non RT-
control MMTV-RIC. Lane 3 = cDNA control. Lane 4 = non RT control. c, 
Quantification of mammary epithelial cell specific MMTV-RIC transgene 
expression in offsprings from lines 2, 3, and 4. Expression levels were determined 
by qRT-PCR on total mRNA isolated from mammary epithelial cells. Data are 
shown relative to endogenous RANK levels in control mice, n=2 mice per group. d, 
RANK qRT-PCR was conducted on total mRNA isolated from multiple tissues 
obtained from females of line 3. Note the high level of transgene expression in the 
thymus. n=3 mice per group. In c, and d, Primers binding endogenous and 
transgenic RANK mRNA were used. Data were normalized to b-actin and are 
shown relative to endogenous RANK levels of age-matched control mice, mean 
values +/- sem. * P > 0,05; ** P > 0.005; *** P > 0.001 (Student`s t-test) 
 
The offsprings of all MMTV-RIC mice are born healthy and do not display any 
overt defects (Figure 16a). Whole mount staining of mammary glands isolated from 
nulliparous female mice revealed that line 3 carriers display a less dense ductal network 
compared to age-matched littermate controls, which needs to be further analyzed. 
However, we could not observe a difference between nulliparous mammary glands of 
the progeny from MMTV-RIC lines 2 and 4 and control littermates. (Figure 16b). None 
of the five founder lines exhibited an obvious lactation defect even after several rounds 
of pregnancy.  
We are currently crossing these transgenic mice to mice with conditionally 
targeted alleles of TRAF6, NFATc1 and IKKα. Since RANK expression is coupled to 
Cre-recombinase activity we are able to overexpress RANK and simultaneously delete 
one of these putative downstream molecules. Afterwards these mice will then be 
challenged with MPA/DMBA to trigger breast cancer. Thus, the MMTV-RIC mice will 
be very useful for understanding the complexity of RANK/RANKL downstream 
signaling in hormone-driven breast cancer in more detail.  
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 Figure 16. a, Female offspring of MMTV-RIC Line 2 are shown at the age 
of 10 days. b, Whole mount staining of mammary glands isolated from 6 week old 
nulliparous offsprings of MMTV-RIC Lines 2, 3 and 4. Ductal sidebranching and 
expansion in the fat pad is comparable between transgenic females of Lines 2 and 4 
and age-matched littermate controls. Line 3 nulliparous females display decreased 
expansion of the epithelial ducts in the fat pad. 
 
 
 
 
 
 
 
 
 
 
 
All experiments shown here were done by me, except the following: Andreas 
Leibbrandt generated the RANKfloxed mice and carried out the RANK-NeuT experiment. 
The Progesterone receptor knockout experiment was carried out by Heather Lee 
(Garvan Institute, Australia) and Daniel Schramek. Daniel Schramek did all the Western 
Blots and cell culture experiments and helped with qRT-PCR, the γ-irradiation 
experiment and the cloning of the MMTV-RIC construct. Histological pictures of 
tumors were taken by Lukas Kenner. Lukas Kenner also did the quantification of 
Carcinomas in situ and Invasive carcinomas.  
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3. Discussion 
Initially RANKL and its receptor RANK were identified as key regulators of 
osteoclastogenesis (Kong et al., 1999b). RANK/RANKL signaling is not only of utmost 
importance for bone metabolism but also crucial in pathologic bone remodeling 
(Leibbrandt and Penninger, 2008). Osteoporosis is one of the diseases which is caused 
by unbalanced RANK/RANKL activity. Especially postmenopausal women who have 
stopped estrogen production in the ovaries are prone to develop osteoporosis, thus 
indicating that RANK/RANKL is strongly influenced by sex hormones (Leibbrandt and 
Penninger, 2008). Surprisingly RANK/RANKL signaling also turned out to be required 
for the development of a lactating mammary gland during pregnancy (Fata et al., 2000). 
By activating the NFκB (Cao et al., 2001) and Id2 (Kim et al., 2006) signaling 
pathways, RANK and RANKL induce the differentiation of terminal endbuds to milk-
secreting loculoalveolar structures (Fata et al., 2000). 
Mammalian evolution may provide a rational reason for linking bone 
metabolism to mammary gland development. The formation of a lactating mammary 
gland allows the mother to provide the offspring with calcium rich milk. Essentially, the 
mothers’ milk is the main calcium resource for newborns and a lack of calcium has 
severe consequences including rickets and heart and brain defects (Theill et al., 2002). 
To meet the increased calcium demand lactating females mobilize internal calcium 
resources by demineralization of their skeletons via the activation of osteoclasts (Cross 
et al., 1995). Thus, around 200 million years ago when the first mammals appeared 
RANK/RANKL might have overtaken the role of a common master regulator for bone 
turnover and pregnancy dependent mammary gland development (Theill et al., 2002). 
Recently Hanada et al. reported that hormone regulated RANK/RANKL signaling 
controls female body temperature, a new function which might explain hot flashes in 
older women undergoing hormonal change (Hanada et al., 2009). Thus, it appears that 
the master regulators of bone metabolism are embedded in the tight regulatory network 
of female sex hormones and reproduction.  
Intriguingly, we now could identify RANK/RANKL signaling as a critical 
mediator of hormone dependent breast cancer. Assessing the role of RANK/RANKL in 
the context of MPA/DMBA-driven breast cancer we observed that mice lacking RANK, 
the receptor of RANKL, in mammary epithelial cells developed mammary tumors 
markedly later than control littermates. Thus, the deletion of RANK significantly 

protects female mice from hormone-induced breast cancer. Mechanistically, our data 
suggest that the progestin derivative MPA triggers massive RANKL expression in the 
mammary gland. Importantly, RANKL expression requires also the expression of the 
prolactin receptor which is already known to critically drive breast cancer (Llovera et 
al., 2000; Oakes et al., 2007). As a consequence of elevated RANKL levels mammary 
epithelial cells enter the cell cycle resulting in markedly increased proliferation rates. 
Moreover, RANKL appears to protect mammary epithelial cells from γ-irradiation 
induced apoptosis. Since proliferation and evading programmed cell death are hallmarks 
of malignant tissue transformation (Hanahan and Weinberg, 2000), our results suggest 
that RANK/RANKL provides mammary epithelial cells with these prerequisites for the 
development of hormone-driven breast cancer. Importantly, clinical data also confirm 
the implication of RANK/RANKL in breast cancer in humans. Analysis of serum taken 
from women over many years revealed that the manifestation of breast cancer but not of 
other cancers can be associated with elevated OPG levels. Simultaneously, soluble 
RANKL levels in most individuals tested declined with the manifestation of breast 
cancer. Thus, according to these data in a prospective human cohort altered OPG-to-
sRANKL levels correlates with new-onset breast cancer. 
There a many questions which still remain to be answered. So far it appears that 
RANK/RANKL signals via the NFκB pathway in MPA/DMBA-induced 
carcinogenesis. Indeed this mechanism seems plausible since NFκB can induce the 
expression of the cell cycle promoter Cyclin D1 (Cao et al., 2001). However, we cannot 
exclude the contribution of other downstream targets in RANK/RANKL controlled 
mammary tumorigenesis. Therefore the MMTV-RIC transgenic mice which we 
generated should be very helpful to better understand the complexity of RANK/RANKL 
downstream signaling pathways. Moreover, additional experiments are required to 
define the role of hormonal pathways in RANK/RANKL signaling in more detail.  
Interestingly, high estrogen levels as well as enhanced local production of 
estrogens are considered as critical primary mediators of breast cancer development in 
obese postmenopausal women (Cleary and Grossmann, 2009). Therefore it would be 
very interesting to test whether RANK/RANKL can also be associated with mammary 
tumors resulting from increased body weight. Another intriguing aspect of 
RANK/RANKL signaling in breast cancer is the following: micro-calcifications and 
anormal tissue density constitute two of the most important markers for early 
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mammographic diagnosis of malignant lesions of the breasts (Mortier et al., 1997). 
Importantly, our data indicate that RANK and RANKL are involved in early events of 
breast carcinogenesis including hyperplasia. Moreover, radiographic mammary 
calcifications occur in 30-50 % of all breast cancer cases (Morgan et al., 2005). Since 
RANK/RANKL control bone mineralization and early events in malign transformations 
of the mammary tissue we predict a reasonable connection between RANK/RANKL 
and micro-calcifications in mammary glands. Although we could not observe a 
difference in mammary tumor onset in NFATc1∆mam and TRAF6∆mam mice it might be 
worth testing whether these signaling pathways could be involved in microcalifications 
of the breasts.  
In conclusion we have uncovered a major and novel pathway which appears to 
be required and sufficient to mediate hormone-induced breast cancer. We postulate that 
our data have some far-reaching implications. Millions of women use progesterone 
derivates in contraceptives and for hormonal replacement therapy. Epidemiologically, 
hormones and in particular progestins like MPA have been linked to an increased risk to 
develop breast cancer (Beral, 2003). For instance, breast cancer is much more prevalent 
in industrial countries were the use of HRT is very frequent and a decrease of breast 
cancer incidence since 1999 is likely to correlate with the decrease of use of HRT 
(Jemal et al., 2009). Since we now suggest for the first time that progestins drive 
mammary carcinogenesis via the RANK/RANKL system new ways for preventing 
and/or treating breast cancer might have been revealed.  
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5. Materials and Methodes  
Mice. Rankfloxed mice have been recently generated in our laboratory (Hanada et al., 
2009). In order to generate a Rank-null allele (RankΔ allele) Rankfloxed mice were crossed 
to ubiquitous deleter mice expressing cre-recombinase under control of the β-actin 
promoter (Lewandoski et al., 1997). For mammary gland specific deletion mice carrying 
the Rankfloxed and RankΔ alleles were crossed to MMTV-Cre mice. Rankfloxed, RankΔ as 
well as MMTV-Cre mice were backcrossed seven times onto a BALBc background 
before generating MMTV-Cre RANKΔ/fl mice. MMTV-Cre mice (Wagner et al., 2001) 
(stock # 00553) and Mx-Cre mice (Kuhn et al., 1995) (stock # 003556) were obtained 
from the Jackson Laboratory. IKKαfloxed mice (Gareus et al., 2007), TRAF6floxed mice 
and NFATc1floxed mice (Aliprantis et al., 2008) have been previously described. 
Genotyping was performed using the following primers:  
Rank: 
Forward Primer: 5’GGCAG AACTC GGATG CACAG ATTGG3’ 
Reverse Primer: 5’AGTGT GCCTG GCATG TGCAG ACCTT3’ 
Mutant allele: 5’CTGGT GGTTG TTCTC CTGGT GTCAT3’  
PCR conditions: 95°C/10s, 60°C/20s, 72°C/32s, 35 cycles 
TRAF6: 
Forward Primer: 5’AGGGC ATATT TGAAG TCCATT3’ 
Reverse Primer: 5’TCTTG CTCTT CAAGA GGATCG3’ 
Mutant allele: 5’TTCAT GGCGT GGTGC TATATA3’ 
PCR conditions: 94°C/30s, 55°C/30s, 72°C/30s, 34 cycles 
IKKα: 
Forward Primer: 5’CGCTT AGTGT GACTG AGGAA C3’ 
Reverse Primer: 5’ATGAG CCCAA CATTT AATCT T3’  
Mutant allele: 5’GGCAT CAGAG TCCGT GGGT3’ 
PCR conditions: 94°C/30s, 55°/30s, 72°C 60s, 35 cycles 
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NFATc1: 
Forward Primer: 5’AAGGA ATTAC TGGGA AGCCT GGCA3’, 
Reverse Primer: 5’AGGGA CTATC ATTTG GCAGG GACA3’  
Mutant allele: 5’ACAGG AAACA GCTCT GTTCC ACAC3’  
PCR conditions: 95°C/10s, 60°C/15s, 72°C/40s, 40 cycles. 
Animal experiments were approved by an ethics committee. Mice were housed 
according to institutional guidelines.  
MPA/DMBA-induced mammary carcinogenesis. 6-week old female mice were 
anesthetized with ketamine-xylamine and surgically implanted with slow-release 
Medroxyprogesterone Acetate pellets (50 mg, 90 days of release, Scientific research of 
America, # NP-161) subcutaneously on the right flank. 200µl DMBA (5mg/ml 
cottonseed oil) was administered by oral gavage 6 times throughout the following 8 
weeks as outlined in Figure 5a. Mammary tumor onset was determined by palpation. 
Histology, whole mount and immunohistochemistry. Mammary glands were isolated 
and fixed over night in Rotihistofix 4%. After dehydration 5 µm paraffin sections were 
cut and stained for hematoxylin and eosin (H&E). Whole mount staining of glands was 
performed as previously described (Fata et al., 1999). Briefly, the fourth inguinal fat 
pads of virgin mice were dissected, placed on a microscope slide and fixed over night in 
4% PFA. The adipose tissue was removed in acetone for 3 hours. For rehydration, 
glands were put in 100% ethanol and 95% ethanol for 1 hour respectively. Glands were 
stained in Hematoxylin for 3 hours and afterwards transferred into slightly basic tap 
water for 2 hours followed by 2 hours of destaining in 50% ethanol acidified with 25ml 
1.0M HCl/liter. After dehydrating in ascending concentrations of ethanol (70%, 95% 
and 100% ethanol, incubation for 1 hour, respectively), glands were stored and xylene. 
For immunoperoxidase staining paraffin sections were incubated with rabbit polyclonal 
anti-Ki67 (Novocastra # 6000224) and anti-active Caspase 3 (Cell Signaling #9661) and 
visualized using 1 to 200 diluted peroxidase-conjugated anti-rabbit IgG (DAKO, # 
E0432). For calculation of proliferation and apoptosis positive epithelial cells were 
divided by the total number of epithelial cells. For Ki67 stainings no fewer than 1000 
nuclei and for active Caspase 3 staining no fewer than 5000 cells were counted per 
section.  
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Isolation of primary mammary epithelial cells. Mammary glands from female 
wildtype mice were isolated, minced under sterile conditions and incubated in a 
collagenase solution (2 mg/ml Collagenase A, Sigma # C274; 5 % FCS; 0,2 % Trypsin, 50 
µg/ml Gentamycin; 5 µg/ml Insulin) for 30 minutes at 100 rpm, 37°C. For all following 
steps pipettes and tubes were precoated in 5% BSA. Fatty layer was removed. Pellet was 
resuspended in 10 ml DMEM/F12 (Invitrogen) and centrifuged for 10 min at 1500 rpm. 
Pellet was resuspended in 4 ml DMEM/F12 and centrifuged at1550 rpm to remove 
fibroblasts. Cleared pellets were resuspended in growth medium and put in culture. 
Western blotting. Primary non/transformed mouse mammary epithelial cells and the 
human epithelial breast tumor cell line SKB3 (Mo and Reynolds, 1996) were stimulated 
using 1µg recombinant RANKL (Oriental yeast # NIB47197900). Cells were lysed in 
RIPA buffer plus phosphatase and protease inhibitor. Samples were loaded onto 8 % 
gels and run using SDS running buffer. Separated proteins were transferred onto a 
membrane using SEMI-DRY Transfer Cell (BIORAD). Blots were blocked with 5% 
BSA in 1xTBS 0.1% Tween-20 (TBST) for 1 hour followed by incubation with primary 
antibody overnight at 4oC (diluted in TBST according to the manufactures protocol). 
Primary antibodies reactive to mouse β-actin (Sigma), phosphorylated (P) NFκB 
(#4767), phosphorylated (P) IκBα (1:1000, # 2859), IkBα (1:1000, # 4814), 
phosphorylated (P) IKKα (1:1000, # 2618), IKKβ (1:1000, # 2678), IKKγ (1:1000, # 
2685), (all from Cell Signaling), were used. Blots were washed in TBST for 30 minutes 
with 2 times of solution change, incubated with HRP-conjugated 2nd antibodies (1:2000, 
Promega, diluted in 3% milk) for 1 hour at room temperature, washed in TBST for 30 
minutes and visualized using ECL.  
qRT-PCR: Total RNA of tumors and of the indicated tissues of MMTV-RIC females 
was extracted using RNeasy Mini Kit (Qiagen # 74104). 2 µg of total RNA was 
converted to cDNA by using Ready to go Beads (GE Healthcare, Cat. No. 27-9264-01) 
and used for quantitative (q)RT-PCR analysis. The following primers were used: 
β-actin: 
Forward Primer: 5’GCTCA TAGCT CTTCT CCAGGG3’ 
Reverse Primer: 5’CCTGA ACCCT AAGGC CAACCG3’  
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RANKL: 
Forward Primer: 5’CTGAG GCCCA GCCAT TTG3’ 
Reverse Primer: 5’GTTGC TTAAC GTCAT GTTAG AGATC TTG3’  
RANK: 
Forward Primer: 5’CTTGG ACACC TGGAA TGAAG3’ 
Reverse Primer: 5’CAGCA CTCGC AGTCT GAGTT3’  
Cyclin D1: 
Forward Primer: 5’CTGTG CGCCC TCCGT ATCT TA3’ 
Reverse Primer: 5’GGCGG CCAGG TTCCA CTTGAG3’  
p21 (Cdkn1a): 
Forward Primer: 5’GTGGC CTTGT CGCTG TCTT3’  
Reverse Primer: 5’GCGCT TGGAG TGATA GAAAT CTG3’ 
In vivo cell death. RANKΔmam and littermate controls were γ-irradiated with a total dose 
of 5 Gray (Gy). After six hours, mice were sacrificed and mammary glands were 
isolated. Cell death was determined by immunostaining using the apoptotic marker 
active Caspase 3 (Cell Signaling #9661). 
Generation of MMTV-RANK-Ires-CRE transgenic mouse lines. The full length 
murine RANK (Tnfrsf11a) cDNA (GenBank accession number: AF019046) was 
directionally inserted into the HindIII-EcoRI sites of pMMTV-SV40. The Ires-Cre 
cDNA was excised from pMMTV-PMT-Ires-Cre as an EcoRI fragment and inserted 
into a corresponding unique EcoRI site 3’ of MMTV-LTR-RANK and 5’ of SV40. The 
vector inserts were sequenced to exclude mutations in the coding regions of the 
construct. Prior to pronuclear injection the MMTV-RANK-Ires-CRE transgene was 
isolated with OliI and SphI from the pBabe cloning vector. The injection fragment was 
recovered by electroelution (QIAquick Gel extraction kit, # 28704) and injected into 
male pronuclei of single-cell (FVB/N) embryos. Viable eggs were subsequently 
transferred to pseudopregnant B6CBAF1 recipients. Founders were identified by PCR 
with the following PCR primers for cre-recombinase 5’TCGCG ATTAT CTTCT 
ATATC TTCAG3’ (forward) and 5’GCTCG ACCAG TTTAG TTACCC3’ (reverse), 
95°C/10s, 58°C/10s, 72°C/30s, 34 cycles. 
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6. Abbreviations  
AIRE Autoimmune regulator 
Akt/PKB Protein kinase 2 
ALPS  Autoimmune lymphoproliferative syndrome 
APC Antigen presenting cell 
ARO Autosomal recessive osteopetrosis 
Bcl-XL B-cell lymphoma-extra large 
c-Fos V-fos FBJ murine osteosarcoma viral oncogene homolog 
c-Jun Jun antigen 
COX2 Cyclooxygenase 2 
DC Dendritic cell 
DMBA Dimethylbenz(a)anthracene 
ErbB2 Human epidermal growth factor receptor 2 
EP3R Prostaglandin E receptor 2 
ERK Extracellular signal-regulated kinase 
Fra Fos related antigen 
GAB2 GRB2 associated binder 2 
GRB2 Growth factor receptor bound protein 2 
HRT Hormonal replacement therapy 
Id2 Inhibitor of DNA binding 2 
IkB Inhibitor kappa B 
IKK IkB kinase 
INF Interferon 
JAK2 Janus kinase 2 
JNK c-Jun N-terminal kinase 
JunB Jun B proto-oncogene 
kDa kilo Dalton 
LTβ Lymphotoxin beta 
MAPK Mitogen activated protein kinase 
M-CSF Macrophage colony stimulating factor 
MKK7 Mitogen activated protein kinase kinase 7 
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MPA Medroxyprogesterone Acetate 
mTEC Medullary thymic epithelial cell 
NFATc1 Nuclear factor of activated T-cells, calcineurin dependent 1 
NFkB Nuclear factor kappa B 
NK cells Natural killer cells 
ODF Osteoclast differentiation factor  
OPG Osteoprotegerin 
OPGL OPG ligand 
PGE2 Prostaglandin E2 
PLC Phospholipase C 
PR Progesterone receptor 
PRAKO Progesterone receptor-A knockout 
PRBKO Progesterone receptor-B knockout 
PRKO Progesterone receptor knockout 
PRL Prolactin 
PTHrP Parathyroid hormone-related peptide 
RANK Receptor activator of NFkB 
RANKL Receptor activator of NFkB ligand 
SHIP1 SH2 (Src homology 2)-containing inositol phosphatase-1 
STAT5 Signal transducer and activator of transcription 2 
TGF Transforming growth factor 
TNF Tumor necrosis factor 
TRAF Tumor necrosis factor related adaptor protein 
TRAIL TNF-related apoptosis-inducing ligand 
TRANCE TNF-related activation-induced cytokine 
Treg Regulatory T cell 
UV Ultraviolet 
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